相关实验视频

Updated: May 22, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

基于经过实验验证的网络药理学的结直肠癌抗击britannin的探索机制

Xiaoli Liu¹, Qiuxia Ye², Mengdi Hao¹

¹Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Naunyn-Schmiedeberg's archives of pharmacology

|March 13, 2025

概括

来自Inula japonica的一种化合物Britannin通过直接影响癌细胞和重编程瘤微环境,特别是通过巨分化,显示出对结直肠癌 (CRC) 的潜力.

科学领域:

药理学药理学是指药理学的学科.
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

英国人展现了各种各样的药理学活动.
英国素的抗癌机制,特别是在结直肠癌 (CRC) 中,仍然在很大程度上未被阐明.
了解britannin的作用对于开发新型CRC疗法至关重要.

研究的目的:

为了研究英国素在结直肠癌中的治疗机制.
为了确定关键的分子标和途径受影响的britannin在CRC.

主要方法:

网络药理学被用来识别CRC中的britannin相关基因.
使用单细胞RNA测序 (scRNA-seq) 和CIBERSORT分析来评估细胞和免疫微环境的变化.
在体外和体内实验验验证了抗癌效应和机械洞察力.

主要成果:

网络药理学确定了36个与英国素相关的基因和涉及的途径,如PI3K-Akt,PD-L1和HIF-1信号传递.
布列塔宁在CRC细胞上表现出直接的抗增殖和亲细胞亡作用,抑制了AKT酸化.
布列塔宁调节了瘤微环境,影响瘤细胞,巨细胞和内皮细胞,特别是通过抑制M1巨细胞极化和抑制瘤生长 in vivo.

结论:

布列塔宁通过直接的细胞毒性和瘤免疫微环境的调制来发挥抗CRC作用.
向巨细胞两极分化代表了Britannin在结肠直肠癌中的抗癌活性的一个关键机制.
英国人作为结直肠癌治疗的治疗剂具有前途.

关键词:

英国人,英国人.结肠直肠癌是一种癌症.巨细胞的两极分化网络药理学网络药理学

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Protein Networks

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...